ChromaDex (NASDAQ:CDXC) Cut to Buy at StockNews.com

StockNews.com lowered shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a research note released on Friday morning.

Several other research firms have also recently commented on CDXC. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Roth Mkm raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

ChromaDex Stock Up 0.5 %

CDXC stock opened at $5.51 on Friday. ChromaDex has a fifty-two week low of $1.36 and a fifty-two week high of $7.97. The firm’s 50-day simple moving average is $6.29 and its 200 day simple moving average is $4.25. The stock has a market cap of $420.87 million, a PE ratio of 551.55 and a beta of 2.21.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same quarter last year, the company earned ($0.01) EPS. Equities analysts forecast that ChromaDex will post 0.04 EPS for the current fiscal year.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

Several institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company bought a new position in shares of ChromaDex in the second quarter valued at approximately $31,000. Merriman Wealth Management LLC bought a new position in ChromaDex during the second quarter worth $32,000. FMR LLC bought a new position in ChromaDex during the third quarter worth $55,000. Marshall Wace LLP bought a new position in ChromaDex during the second quarter worth $56,000. Finally, SG Americas Securities LLC bought a new position in ChromaDex during the third quarter worth $61,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.